• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    106.31 +1.11 (+1.06%)
    Streaming Delayed Price Updated: 3:43 PM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ligand Pharm

    < Previous 1 2 3 4 5 6 Next >
    Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Looking Into Ligand Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
    After Monday's panicked global sell-off, markets have calmed down. 
    Via Investor's Business Daily
    LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
    Via Benzinga
    Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
    Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
    Via Investor's Business Daily
    Ligand Reports Second Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    5 Best Short-Term Stocks to Consider Investing In
    Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. 
    Via MarketBeat
    Ligand to Acquire APEIRON Biologics AG for $100 Million
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Lifecore Biomedical Announces Cooperation Agreement with 22NW
    Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
    From Lifecore Biomedical, Inc.
    Via GlobeNewswire
    Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Participate in Upcoming Investor Conferences
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    3 Magnificent Growth Stocks to Buy Hand Over Fist
    Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
    Via The Motley Fool
    Topics Economy
    Exposures Interest Rates
    3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
    With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
    Via InvestorPlace
    LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Ligand Reports First Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
    While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... 
    Via Talk Markets
    Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    7 Small-Cap Stocks for the Thinking Speculator
    While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. 
    Via InvestorPlace
    Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
    Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. 
    Via Benzinga
    Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.